Evidence map›Paper›PMID 36118230›Full record

ArticleFrontiers in microbiology2022

Microbial and human transcriptional profiling of coronavirus disease 2019 patients: Potential predictors of disease severity.

Hairun Gan, Jiumeng Min, Haoyu Long, Bing Li, Xinyan Hu, Zhongyi Zhu, Luting Li, Tiancheng Wang, Xiangyan He, Jianxun Cai and 14 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Hairun GanCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Jiumeng MinBGI PathoGenesis Pharmaceutical Technology, BGI-Shenzhen, Shenzhen, China.
Haoyu LongCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Bing LiDepartment of Ophthalmology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Xinyan HuCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Zhongyi ZhuBGI PathoGenesis Pharmaceutical Technology, BGI-Shenzhen, Shenzhen, China.
Luting LiCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Tiancheng WangCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Xiangyan HeBGI PathoGenesis Pharmaceutical Technology, BGI-Shenzhen, Shenzhen, China.
Jianxun CaiCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Yongyu ZhangCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Jianan HeCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Luan ChenBGI PathoGenesis Pharmaceutical Technology, BGI-Shenzhen, Shenzhen, China.
Dashuai WangCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Jintao SuBGI PathoGenesis Pharmaceutical Technology, BGI-Shenzhen, Shenzhen, China.
Ni ZhaoCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Weile HuangCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Jingjing ZhangCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Ziqi SuBGI PathoGenesis Pharmaceutical Technology, BGI-Shenzhen, Shenzhen, China.
Hui GuoCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Xiaojun HuCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Junjie MaoCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Jinmin MaBGI PathoGenesis Pharmaceutical Technology, BGI-Shenzhen, Shenzhen, China.
Pengfei PangCenter for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
BGI Group (China) · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high morbidity of patients with coronavirus disease 2019 (COVID-19) brings on a panic around the world. COVID-19 is associated with sex bias, immune system, and preexisting chronic diseases. We analyzed the gene expression in patients with COVID-19 and in their microbiota in order to identify potential biomarkers to aid in disease management. A total of 129 RNA samples from nasopharyngeal, oropharyngeal, and anal swabs were collected and sequenced in a high-throughput manner. Several microbial strains differed in abundance between patients with mild or severe COVID-19. Microbial genera were more abundant in oropharyngeal swabs than in nasopharyngeal or anal swabs. Oropharyngeal swabs allowed more sensitive detection of the causative SARS-CoV-2. Microbial and human transcriptomes in swabs from patients with mild disease showed enrichment of genes involved in amino acid metabolism, or protein modification

Indexed as

COVID-19diagnostic biomarkershost responsemicrobiomeSARS-CoV-2transcriptomic sequencing

Identifiers

PMID36118230
PMCPMC9479730
OpenAlexW4294275903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.